Adalimumab Improves Quality of Life in Psoriasis Patients
Author Information
Author(s): Revicki Dennis A, Menter Alan, Feldman Steven, Kimel Miriam, Harnam Neesha, Willian Mary K
Primary Institution: United BioSource Corporation
Hypothesis
Does adalimumab improve health-related quality of life in patients with moderate to severe plaque psoriasis compared to the general population?
Conclusion
Adalimumab treatment improved health-related quality of life for psoriasis patients to levels comparable to or better than the general US population.
Supporting Evidence
- Patients receiving adalimumab showed significant improvements in both physical and mental health scores.
- At Week 16, adalimumab patients had higher PCS scores than the general population.
- MCS scores for adalimumab patients were similar to the general population, while placebo patients had lower scores.
Takeaway
This study shows that a medicine called adalimumab helps people with psoriasis feel better and live happier lives, just like people without the disease.
Methodology
Patients with moderate to severe psoriasis were randomized to receive either adalimumab or placebo, and their health-related quality of life was assessed using the SF-36 Health Survey.
Potential Biases
Self-reported data may lead to under- or overestimation of health-related quality of life.
Limitations
The analysis was based only on US normative data, and self-reported health status may introduce bias.
Participant Demographics
The study included 1,205 patients with moderate to severe plaque psoriasis, with a mean age of approximately 44 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website